FDA Concerns About Cancer Risk Sink Fulcrum Therapeutics’ Sickle Cell Disease Drug
Fulcrum Therapeutics drug pociredir posted early clinical trial results showing signs of treating sickle cell disease with no reports of serious complications. But the biotech is discontinuing this program due to FDA concerns that drugs in this class of medicines raise the risk of cancer.
What Data Delays Are Costing Healthcare — And Its Patients
Timely, usable data closes care gaps and improves operations, but healthcare organizations lack access.
AI for MSK Will Bend the Healthcare Cost Curve
Access to AI-powered digital MSK care options reduces wait times and allows patients to move directly into the right care instead of stair-stepping from hospital inpatient to primary care physicians to physical therapy.
Medical Weight Loss is Rapidly Changing Surgical Risk and Costs
When used thoughtfully, with attention to muscle preservation and long-term sustainability, medical weight loss can lower complication rates, support a steadier recovery and reduce downstream strain on both patients and health systems.
Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise Therapeutics
France-based pharma company Servier is acquiring the muscular dystrophy business of Edgewise Therapeutics as part of a revenue growth strategy in oncology and neurology. The deal brings an Edgewise drug in clinical development for two rare neuromuscular disorders with limited treatment options.